Cargando…
Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-κB/mTOR signaling proteins and anti-apoptotic Bcl-2
Lack of effective therapeutics for pancreatic cancer at the present time underscores the dire need for safe and effective agents for the treatment of this malignancy. In the present study, we have evaluated the anticancer activity and the mechanism of action of pristimerin (PM), a quinonemethide tri...
Autores principales: | DEEB, DORRAH, GAO, XIAOHUA, LIU, YONG BO, PINDOLIA, KIRIT, GAUTAM, SUBHASH C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027926/ https://www.ncbi.nlm.nih.gov/pubmed/24603988 http://dx.doi.org/10.3892/ijo.2014.2325 |
Ejemplares similares
-
Inhibition of hTERT/telomerase contributes to the antitumor activity of pristimerin in pancreatic ductal adenocarcinoma cells
por: DEEB, DORRAH, et al.
Publicado: (2015) -
Ubiquitin-proteasomal degradation of antiapoptotic survivin facilitates induction of apoptosis in prostate cancer cells by pristimerin
por: LIU, YONG BO, et al.
Publicado: (2014) -
Induction of Apoptosis in Pancreatic Cancer Cells by CDDO-Me Involves Repression of Telomerase through Epigenetic Pathways
por: Deeb, Dorrah, et al.
Publicado: (2014) -
Telomerase Reverse Transcriptase (TERT) is a Therapeutic Target of Oleanane Triterpenoid CDDO-Me in Prostate Cancer
por: Liu, Yongbo, et al.
Publicado: (2012) -
CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer
por: Deeb, Dorrah, et al.
Publicado: (2010)